Fierce Biotech September 30, 2022
Gabrielle Masson

There are 200-some cell and gene companies actively conducting phase 3 clinical trials. 

As the cell and gene field builds off a quarter of great scientific progress, the industry may be teetering on the brink of transforming medicine as we know it.

At the Fierce Biotech Summit last week, Avrobio CEO Geoff MacKay shared his insight on the current cell and gene landscape, and what the outlook is like for reimbursement once more programs pass the FDA threshold. He pointed to an estimated15 companies in the field preparing to file for approval with the agency in 2023.

“You can slice and dice that any way you want,” the CEO of the Massachusetts-based...

Today's Sponsors

LEK
Teladoc Health
Amwell

Today's Sponsors

LEK
Teladoc Health

Today's Sponsor

Oliver Wyman

 
Topics: Biotechnology, Clinical Trials, Conferences / Podcast, Pharma / Biotech, Trends
Researchers use mRNA technology for potential universal flu vaccine
Top 25 women biotech leaders of 2022, per Healthcare Technology Report
Here’s why we’re not prepared for the next wave of biotech innovation
Julie Wolf: Investing in Biotech and Digital Health Innovation
Supercharging mRNA Vaccines With Self-Amplifying RNA Technology